These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34660273)

  • 1. The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis.
    Wang DY; Chen Y; Zhang Y; Shen YQ
    Front Oncol; 2021; 11():705866. PubMed ID: 34660273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Tan L; Liu J; Liu X; Chen J; Yan Z; Yang H; Zhang D
    J Exp Clin Cancer Res; 2009 Sep; 28(1):131. PubMed ID: 19775450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
    Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
    Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial Sequential Analysis and Meta-Analysis of Olanzapine in Pediatric Patients for Chemotherapy-Induced Nausea and Vomiting (CINV).
    Singh A; Gupta D; Kannauje PK; Agrawal AK
    Hosp Pharm; 2024 Aug; 59(4):415-426. PubMed ID: 38919763
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
    Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
    Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
    Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
    J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
    Chelkeba L; Gidey K; Mamo A; Yohannes B; Matso T; Melaku T
    Pharm Pract (Granada); 2017; 15(1):877. PubMed ID: 28503222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
    Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
    ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
    Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I
    Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
    Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
    Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
    van der Vorst MJ; Neefjes EC; Konings IR; Verheul HM
    Support Care Cancer; 2015 Aug; 23(8):2499-506. PubMed ID: 26041480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.